Professor David Preiss
David Preiss
PhD FRCPath MRCP
Professor of Metabolic Medicine and Clinical Trials
- Honorary Consultant in Metabolic Medicine
David was appointed as a Senior Clinical Research Fellow at the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) in September 2015 and as Associate Professor in 2016.
He is a previous BHF Centre for Research Excellence Senior Transition Fellow and leads the module on Clinical Trial Reporting and Meta-analyses in the University's MSc in Clinical Trials.
His major interest is the prevention of cardiovascular and microvascular disease with particular focus on lipid modification and diabetes. His current research combines clinical trials, epidemiological studies and meta-analyses of major studies.
Current projects include:
- ASCEND PLUS: a randomised trial investigating the effect of the GLP1 receptor agonist, oral semaglutide, on major cardiovascular events in 20,000 participants with type 2 diabetes.
- LENS: a randomised trial investigating the effect of the cholesterol and triglyceride-lowering drug, fenofibrate, on the progression of diabetic eye disease in 1,150 participants with diabetes and observable retinopathy or maculopathy.
- ORION-4: a randomised trial investigating the effect of the LDL cholesterol-lowering drug, inclisiran, on major cardiovascular events in 16,000 participants with cardiovascular disease.
- EMPA-KIDNEY: a randomised trial investigating the effect of the SGLT2 inhibitor, empagliflozin, on worsening of kidney disease or cardiovascular death in 6,600 participants with chronic kidney disease.
- Cholesterol Treatment Trialists' Collaboration: analyses of adverse event data from randomised controlled trials of statin therapy.
David studied medicine at the University of Pretoria, South Africa and, after junior doctor training posts in medicine and biochemistry in Scotland, qualified as a consultant in Chemical Pathology and Metabolic Medicine in Glasgow in 2012.
He completed his thesis, examining the links between glycaemia and cardiovascular disease, in 2011/2012 and was awarded the University of Glasgow’s Bellahouston Medal for this research.
He was recipient of a Rising Star Fellowship from the European Foundation for the Study of Diabetes in 2013, and was also awarded the Royal College of Pathology’s Research Medal for Clinical Biochemistry in 2010.
Recent publications
-
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Journal article
Mayne KJ. et al, (2024), Nephrol Dial Transplant
-
Design, recruitment and baseline characteristics of the LENS trial.
Journal article
LENS Collaborative Group None., (2024), Diabet Med, 41
-
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Journal article
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
-
Effect of Fenofibrate on Progression of Diabetic Retinopathy.
Journal article
Preiss D. et al, (2024), NEJM Evid
-
Association of daily steps with incident non-alcoholic fatty liver disease: Evidence from the UK Biobank cohort
Preprint
Fulda ES. et al, (2024)
-
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
Journal article
Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319
-
Diabetic Retinopathy and Quality of Life: A Systematic Review and Meta-Analysis.
Journal article
Zayed MG. et al, (2024), JAMA Ophthalmol
-
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
Journal article
Mayne KJ. et al, (2024), J Am Soc Nephrol, 35, 202 - 215
-
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 51 - 60
-
Quality of care for secondary cardiovascular disease prevention in 2009- 2017: population-wide cohort study of antiplatelet therapy use in Scotland
Journal article
PREISS D. et al, (2023), BMJ Quality and Safety